7 Hills Pharma Revenue and Competitors

Houston, TX USA

Location

N/A

Total Funding

Biotech

Industry

Estimated Revenue & Valuation

  • 7 Hills Pharma's estimated annual revenue is currently $1.2M per year.(i)
  • 7 Hills Pharma's estimated revenue per employee is $77,500

Employee Data

  • 7 Hills Pharma has 16 Employees.(i)
  • 7 Hills Pharma grew their employee count by 23% last year.

7 Hills Pharma's People

NameTitleEmail/Phone
1
President & CEOReveal Email/Phone
2
Chief Financial OfficerReveal Email/Phone
3
VP Clinical and Regulatory AffairsReveal Email/Phone
4
Senior Director, DevelopmentReveal Email/Phone
5
Chair the Board Directors and InvestorReveal Email/Phone
6
Advisor & CollaboratorReveal Email/Phone
7
Outside IP CounselReveal Email/Phone
Competitor NameRevenueNumber of EmployeesEmployee GrowthTotal FundingValuation
#1
$2.5M1645%N/AN/A
#2
$13.8M89-7%N/AN/A
#3
$18.6M1203%$1.8MN/A
#4
$0.9M6-40%N/AN/A
#5
$4.2M270%N/AN/A
#6
$3.4M2247%N/AN/A
#7
$9.6M6229%N/AN/A
#8
$0.9M620%N/AN/A
#9
$1.7M1110%N/AN/A
#10
$15.2M98-8%N/AN/A
Add Company

What Is 7 Hills Pharma?

7 Hills Pharma is a clinical-stage pharmaceutical company developing first-in-concept, oral immune stimulants to augment a broad range of immunotherapies for the treatment of drug-resistant solid tumors and prevention of infectious diseases. Our compounds are selective, allosteric, systemic activators of the integrins LFA-1 and VLA-4 that have been shown in preclinical models to augment the effectiveness of prophylactic vaccines for influenza, COVID-19, Tuberculosis, and Chagas disease, as well as checkpoint inhibitors for solid tumors. Our lead molecule, 7HP349, has completed a Phase I first-in-human clinical trial, demonstrating oral bioavailability and an exceptional safety profile at exposures well exceeding therapeutic levels.

keywords:N/A

N/A

Total Funding

16

Number of Employees

$1.2M

Revenue (est)

23%

Employee Growth %

N/A

Valuation

N/A

Accelerator

Company NameRevenueNumber of EmployeesEmployee GrowthTotal Funding
#1
$2.9M16N/AN/A
#2
$1.4M16N/AN/A
#3
$3.1M16-33%N/A
#4
$2.4M160%N/A
#5
$1.2M1623%$10M